← Back to Clinical Trials
Recruiting NCT07269847

NCT07269847 Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07269847
Status Recruiting
Phase
Sponsor National Cattlemen's Beef Association, a contractor to the Beef Checkoff
Condition Metabolic Syndrome (MetS)
Study Type INTERVENTIONAL
Enrollment 56 participants
Start Date 2026-02-10
Primary Completion 2026-09-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 74 Years
Study Type INTERVENTIONAL
Interventions
Healthy Beef-Centric DietHealthy U.S.-Style Dietary Pattern

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 56 participants in total. It began in 2026-02-10 with a primary completion date of 2026-09-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized study will be conducted to compare the effect of a healthy beef-centric diet to a healthy U.S.-style dietary pattern on inflammation and other metabolic health outcomes in a metabolic syndrome and/or pre-diabetic population.

Eligibility Criteria

Inclusion Criteria: * Participant must be 18 - 74 years of age (inclusive) at the time of signing the informed consent. * Have a BMI range of 23.0 - 39.9 kg/m2 (inclusive). * In otherwise generally good health as determined by the investigator. * Have blood hs-CRP levels equal to or greater than 2.0 mg/L at screening. * Have the following conditions at screening: 1. Pre-diabetes (defined as an HbA1c of 5.7-6.4% \[inclusive\]), and/or 2. MetS, i.e., have 3 of the 5 following metabolic criteria: * A waist circumference of more than 40 inches (102 cm) in men and 35 inches (88 cm) in women * Serum triglycerides level of 150 mg/dL (1.7 mmol/L) or greater * Reduced HDL cholesterol, less than 40 mg/dL (1.0 mmol/L) in men or less than 50 mg/dL (1.3 mmol/L) in women * Elevated fasting glucose of 100 mg/dL (5.6 mmol/L) or greater * Blood pressure values of systolic 130 mmHg or higher or diastolic 85 mmHg or higher * Report low to moderate levels of physical activity, as defined by a "low" or "moderate" activity classification on the IPAQ-SF (if ≤69 YOA) or IPAQ-E (if ≥70 YOA) at screening. * Consume meat-based protein as a part of their normal diet and regularly consume beef. * Not currently using, defined as ≤ 3 uses in the past 3 months prior to Visit 2, any nicotine containing products (patches, gums, vapes, etc.), and willing to abstain for 14 days before Visit 2 until the last procedure. * Have maintained a stable, self-reported body weight for at least 6 months prior to screening (maximum ±10% change in self-reported body weight). * Willing and able to consume all aspects of either study dietary intervention. * Willing to adhere to all study dietary intervention prohibitions and restrictions. * Have maintained consistent dietary habits, including medication and supplement intake, and lifestyle for the last 3 months before screening and agree to maintain them throughout the study (unless required per the restrictions). * Agree to follow the restrictions on concomitant treatments. * Agree to follow the restrictions on lifestyle. * Agree to avoid pregnancy throughout the study if of childbearing potential by using any preferred contraceptive method. * Willing and able to agree to the requirements of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures. Exclusion Criteria: * Individuals who are lactating, planning to become pregnant during the study, or pregnant as confirmed by a positive pregnancy test at Visit 2. * Have a known sensitivity, intolerability, or allergy to any of the components of the study dietary interventions and/or CGM sensor. * Have followed and maintained a ketogenic, Mediterranean, low-carbohydrate, vegetarian, vegan or any other special diet in the 3 months prior to screening. * Have been diagnosed with Type I or II diabetes or thyroid disease. * Have blood pressure of ≥ 160 systolic or ≥ 100 diastolic mmHg. * Have a history or current diagnosis of eating disorders such as anorexia or bulimia. * Have current symptoms, or symptoms within the past 7 days, of an acute infection (e.g., fever, respiratory symptoms such as persistent cough or difficulty breathing), that may influence study outcomes as assessed by the investigator. * Have medical condition(s) known to interfere with absorption, distribution, metabolism, or excretion of protein, fat, or micronutrients (e.g., Crohn's disease, short bowel, acute or chronic pancreatitis, or pancreatic insufficiency). * Have a history of gallbladder disease (e.g., cholelithiasis, cholecystitis), cholecystectomy, gout, or kidney stones. * Have a history of heart/cardiovascular disease, renal disease (dialysis or renal failure), hepatic impairment/disease, immune disorders and/or immunocompromised (i.e., HIV/AIDS). * Have a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) with recovery occurring within 5 years before the screening visit. * Are receiving treatments for or have been hospitalized in the last 12 months for psychiatric disorders (e.g., depression, bipolar disorder, schizophrenia, etc.). * Major surgery in 3 months prior to screening or planned major surgery during the study. * Have a history of alcohol or substance abuse in the 12 months prior to screening (including having been hospitalized for such an in-patient or out-patient intervention program) or use that in the opinion of the investigator may be a concern for the study. * Current enrollment or past participation in another study with either any product(s) with at least one active ingredient or a dietary intervention, within 28 days before screening or longer, if the previous test product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of current study. * Living in the same household as another currently enrolled participant in the present study. * Any other medical condition/situation or use of medications/supplements/therapies that, in the opinion of the investigator, may adversely affect the participant's ability to participate in the study or its measures or pose a significant risk to the participant.

Contact & Investigator

Central Contact

Adam Kuttenkeuler

✉ akuttenkeuler@nutrasource.ca

📞 519-341-3367

Principal Investigator

Shalene McNeill

STUDY CHAIR

National Cattlemen's Beef Association (NCBA), a contractor to the Beef Checkoff

Frequently Asked Questions

Who can join the NCT07269847 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 74 Years, studying Metabolic Syndrome (MetS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07269847 currently recruiting?

Yes, NCT07269847 is actively recruiting participants. Contact the research team at akuttenkeuler@nutrasource.ca for enrollment information.

Where is the NCT07269847 trial being conducted?

This trial is being conducted at Guelph, Canada.

Who is sponsoring the NCT07269847 clinical trial?

NCT07269847 is sponsored by National Cattlemen's Beef Association, a contractor to the Beef Checkoff. The principal investigator is Shalene McNeill at National Cattlemen's Beef Association (NCBA), a contractor to the Beef Checkoff. The trial plans to enroll 56 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology